Publications by authors named "M J Overman"

Depression and anxiety are associated with deficits in adjusting learning behaviour to changing outcome contingencies. This is likely to drive and maintain symptoms, for instance, by perpetuating negative biases or a sense of uncontrollability. Normalising such deficits in adaptive learning might therefore be a novel treatment target for affective disorders.

View Article and Find Full Text PDF

Purpose: Appendiceal adenocarcinoma (AA) is a rare malignancy with distinct histopathologic subtypes and a natural history with metastasis primarily limited to the peritoneum. Little is known about the molecular pathogenesis of AA relative to common tumors.

Experimental Design: We analyzed molecular data for patients within the Guardant Health database with appendix cancer (n = 718).

View Article and Find Full Text PDF

Purpose: Mismatch repair deficient (dMMR) tumors have demonstrated favorable responses to immune checkpoint inhibition targeting PD-1. However, more in-depth identification of predictors of response could further refine patient selection for immunotherapy treatment.

Experimental Design: We undertook integrated evaluation performed on samples collected from 28 of 42 patients enrolled on the NCI-MATCH arm Z1D trial that evaluated PD-1 inhibition treatment with nivolumab in patients with non-colorectal dMMR tumors.

View Article and Find Full Text PDF
Article Synopsis
  • PD-1 inhibition shows effectiveness in treating patients with mismatch repair deficient (dMMR) solid tumors; however, routine testing for dMMR using immunohistochemistry (IHC) is not common across different tumor types.
  • A study involving over 15,000 solid tumor patients demonstrated that next-generation sequencing (NGS) can help identify mutations in MMR genes, revealing a correlation with IHC results in those tested.
  • The findings indicate that patients with MMR mutations showed a significant rate of dMMR, highlighting the potential benefits of employing IHC testing on patients with identified MMR mutations to optimize treatment options.
View Article and Find Full Text PDF

Background: Immune checkpoint blockade (ICB) has revolutionized treatment of mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC). However, there is no evidence on the optimal treatment duration. We aimed to compare outcomes of different immunotherapy durations.

View Article and Find Full Text PDF